EC Number   |
Activating Compound |
Reference |
|---|
    2.2.1.1 | benfotiamine |
- |
695145 |
| 2.2.1.1 | thiamine |
- |
704746 |
| 2.2.1.1 | ethanol |
activation, 1-10% v/v |
486006 |
| 2.2.1.1 | cysteine |
activation, 10 mM |
486006 |
| 2.2.1.1 | more |
active centers of the enzyme are functionally nonequivalent with respect to ribose 5-phosphate binding |
690697 |
| 2.2.1.1 | more |
highest productivity unter slightly aerobic conditions |
704746 |
| 2.2.1.1 | more |
increased levels of TKTL1 transcript in tumors compared with their corresponding normal tissues. Positive correlation between TKTL1 protein expression in primary tumors and the number of metastatic lymph-nodes as well as the diameter of the largest metastatic area in lymph-nodes. High levels of TKTL1 transcript are a relevant phenomenon in small PTCs |
691583 |
| 2.2.1.1 | thiamin |
increases abnormal erythrocyte transketolase activity |
692208 |
| 2.2.1.1 | oxythiamine |
inhibitor of human enzyme, is not inhibitory up to 0.03 mM. Instead, oxythiamine, at this concentration, increases the rate of the reaction by 30% under the assay conditions tested |
720609 |
| 2.2.1.1 | benfotiamine |
not inhibitory on proliferation of insulinoma cell line INS-1. Treatment activates glucose metabolism in INS-1 cells in high-glucose culture conditions and maximizes the cells' ability to synthesize insulin. Treatment activates glucokinase |
695145 |
